Mercado global de tratamento da distrofia muscular de Duchenne – Tendências do setor e previsão para 2030

TABLE 1 LIST OF PRICES FOR APPROVED DRUGS OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET

TABLE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE , 2021-2030 (USD THOUSAND)

TABLE 3 GLOBAL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 GLOBAL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 6 GLOBAL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 GLOBAL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 GLOBAL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 11 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 12 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 13 GLOBAL MUTATION SUPPRESSION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 14 GLOBAL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 15 GLOBAL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 16 GLOBAL CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND)

TABLE 18 GLOBAL PARENTERAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 GLOBAL ORAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USERS, 2021-2030 (USD THOUSAND)

TABLE 22 GLOBAL HOSPITALS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 GLOBAL SPECIALITY CLINICS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 GLOBAL HOMECARE IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 27 GLOBAL HOSPITAL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 GLOBAL RETAIL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 GLOBAL ONLINE PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) COUNTRY

TABLE 32 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 33 NORTH AMERICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 34 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 35 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 36 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 37 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 38 NORTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 NORTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 40 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 43 NORTH AMERICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 45 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 46 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 47 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 48 U.S. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 51 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 52 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 54 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 55 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 57 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 58 U.S.DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 59 U.S. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 60 U.S. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 61 U.S. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 62 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 63 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 64 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 65 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 66 CANADA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 67 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 68 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 69 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 70 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 72 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 73 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 74 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 75 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 76 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 77 CANADA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 78 CANADA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 79 CANADA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 80 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 81 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 82 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 83 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 MEXICO MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 87 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 88 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 89 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 90 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 91 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 93 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 94 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 95 MEXICO EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 96 MEXICO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 97 MEXICO CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 98 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 99 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 100 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 101 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 102 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 EUROPE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 104 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 105 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 106 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 108 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 110 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 111 EUROPE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 112 EUROPE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 113 EUROPE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 114 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 115 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 116 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 117 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 GERMANY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 121 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 122 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 124 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 125 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 126 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 127 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 128 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 129 GERMANY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 130 GERMANY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 131 GERMANY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 132 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 133 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 134 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 135 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 FRANCE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 137 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 139 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 140 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 142 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 143 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 145 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 146 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 147 FRANCE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 148 FRANCE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 149 FRANCE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 150 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 151 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 152 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 153 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 U.K. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 157 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 158 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 159 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 160 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 161 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 163 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 164 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 165 U.K. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 166 U.K. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 167 U.K. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 168 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 169 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 170 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 171 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 ITALY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 174 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 175 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 176 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 178 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 179 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 181 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 182 ITALYDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 183 ITALY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 184 ITALY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 185 ITALY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 186 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 187 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 188 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 189 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 SPAIN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 191 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 192 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 193 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 194 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 195 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 196 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 197 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 199 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 200 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 201 SPAIN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 202 SPAIN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 203 SPAIN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 204 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 205 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 206 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 207 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 RUSSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 209 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 211 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 212 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 214 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 215 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 217 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 218 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 219 RUSSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 220 RUSSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 221 RUSSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 222 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 223 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 224 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 225 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 TURKEY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 227 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 228 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 229 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 230 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 232 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 233 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 234 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 235 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 236 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 237 TURKEY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 238 TURKEY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 239 TURKEY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 240 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 241 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 242 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 243 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 244 BELGIUM MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 247 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 248 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 249 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 250 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 251 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 252 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 253 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 254 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 255 BELGIUM EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 256 BELGIUM DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 257 BELGIUM CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 258 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 259 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 260 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 261 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 NETHERLANDS MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 263 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 264 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 265 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 266 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 267 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 268 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 269 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 270 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 271 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 272 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 273 NETHERLANDS EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 274 NETHERLANDS DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 275 NETHERLANDS CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 276 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 277 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 278 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 279 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 280 SWITZERLAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 282 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 283 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 284 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 285 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 286 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 287 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 288 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 289 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 290 SWITZERLANDDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 291 SWITZERLAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 292 SWITZERLAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 293 SWITZERLAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 294 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 295 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 296 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 297 REST OF EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 298 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 299 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 300 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 301 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 302 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 303 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 304 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 305 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 306 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 307 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 308 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 309 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 310 ASIA-PACIFIC CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 311 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 312 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 313 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 314 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 315 CHINA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 316 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 317 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 318 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 319 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 320 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 321 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 322 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 323 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 324 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 325 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 326 CHINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 327 CHINA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 328 CHINA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 329 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 330 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 331 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 332 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 333 JAPAN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 334 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 335 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 336 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 337 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 338 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 339 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 340 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 341 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 342 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 343 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 344 JAPAN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 345 JAPAN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 346 JAPAN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 347 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 348 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 349 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 350 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 351 INDIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 352 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 353 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 354 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 355 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 356 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 357 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 358 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 359 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 360 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 361 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 362 INDIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 363 INDIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 364 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 365 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 366 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 367 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 368 SOUTH KOREA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 369 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 370 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 371 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 372 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 373 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 374 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 375 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 376 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 377 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 378 SOUTH KOREADUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 379 SOUTH KOREA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 380 SOUTH KOREA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 381 SOUTH KOREA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 382 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 383 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 384 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 385 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 386 AUSTRALIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 387 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 388 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 389 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 390 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 391 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 392 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 393 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 394 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 395 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 396 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 397 AUSTRALIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 398 AUSTRALIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 399 AUSTRALIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 400 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 401 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 402 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 403 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 404 SINGAPORE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 405 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 406 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 407 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 408 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 409 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 410 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 411 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 412 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 413 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 414 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 415 SINGAPORE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 416 SINGAPORE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 417 SINGAPORE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 418 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 419 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 420 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 421 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 422 THAILAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 423 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 424 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 425 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 426 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 427 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 428 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 429 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 430 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 431 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 432 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 433 THAILAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 434 THAILAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 435 THAILAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 436 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 437 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 438 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 439 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 440 MALAYSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 441 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 442 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 443 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 444 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 445 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 446 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 447 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 448 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 449 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 450 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 451 MALAYSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 452 MALAYSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 453 MALAYSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 454 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 455 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 456 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 457 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 458 INDONESIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 459 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 460 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 461 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 462 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 463 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 464 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 465 INDONESIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 466 INDONESIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 467 INDONESIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 468 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 469 INDONESIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 470 INDONESIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 471 INDONESIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 472 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 473 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 474 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 475 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 476 PHILIPPINES MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 477 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 478 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 479 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 480 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 481 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 482 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 483 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 484 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 485 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 486 PHILIPPINESDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 487 PHILIPPINES EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 488 PHILIPPINES DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 489 PHILIPPINES CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 490 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 491 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 492 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 493 REST OF ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 494 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 495 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 496 SOUTH AMERICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 497 SOUTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 498 SOUTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 499 SOUTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 500 SOUTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 501 SOUTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 502 SOUTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 503 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 504 SOUTH AMERICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 505 SOUTH AMERICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 506 SOUTH AMERICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 507 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 508 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 509 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 510 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 511 BRAZIL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 512 BRAZIL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 513 BRAZIL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 514 BRAZIL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 515 BRAZIL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 516 BRAZIL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 517 BRAZIL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 518 BRAZIL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 519 BRAZIL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 520 BRAZIL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 521 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 522 BRAZIL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 523 BRAZIL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 524 BRAZIL CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 525 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 526 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 527 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 528 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 529 ARGENTINA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 530 ARGENTINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 531 ARGENTINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 532 ARGENTINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 533 ARGENTINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 534 ARGENTINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 535 ARGENTINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 536 ARGENTINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 537 ARGENTINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 538 ARGENTINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 539 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 540 ARGENTINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 541 ARGENTINA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 542 ARGENTINA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 543 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 544 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 545 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 546 REST OF SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 547 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 548 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 549 MIDDLE EAST AND AFRICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 550 MIDDLE EAST AND AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 551 MIDDLE EAST AND AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 552 MIDDLE EAST AND AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 553 MIDDLE EAST AND AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 554 MIDDLE EAST AND AFRICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 555 MIDDLE EAST AND AFRICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 556 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 557 MIDDLE EAST AND AFRICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 558 MIDDLE EAST AND AFRICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 559 MIDDLE EAST AND AFRICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 560 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 561 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 562 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 563 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 564 SOUTH AFRICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 565 SOUTH AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 566 SOUTH AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 567 SOUTH AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 568 SOUTH AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 569 SOUTH AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 570 SOUTH AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 571 SOUTH AFRICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 572 SOUTH AFRICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 573 SOUTH AFRICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 574 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 575 SOUTH AFRICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 576 SOUTH AFRICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 577 SOUTH AFRICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 578 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 579 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 580 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 581 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 582 SAUDI ARABIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 583 SAUDI ARABIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 584 SAUDI ARABIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 585 SAUDI ARABIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 586 SAUDI ARABIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 587 SAUDI ARABIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 588 SAUDI ARABIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 589 SAUDI ARABIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 590 SAUDI ARABIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 591 SAUDI ARABIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 592 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 593 SAUDI ARABIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 594 SAUDI ARABIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 595 SAUDI ARABIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 596 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 597 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 598 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 599 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 600 U.A.E MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 601 U.A.E ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 602 U.A.E ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 603 U.A.E ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 604 U.A.E NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 605 U.A.E NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 606 U.A.E NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 607 U.A.E STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 608 U.A.E STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 609 U.A.E STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 610 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 611 U.A.E EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 612 U.A.E DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 613 U.A.E CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 614 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 615 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 616 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 617 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 618 EGYPT MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 619 EGYPT ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 620 EGYPT ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 621 EGYPT ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 622 EGYPT NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 623 EGYPT NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 624 EGYPT NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 625 EGYPT STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 626 EGYPT STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 627 EGYPT STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 628 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 629 EGYPT EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 630 EGYPT DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 631 EGYPT CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 632 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 633 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 634 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 635 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 636 ISRAEL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 637 ISRAEL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 638 ISRAEL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 639 ISRAEL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 640 ISRAEL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 641 ISRAEL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 642 ISRAEL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 643 ISRAEL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 644 ISRAEL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 645 ISRAEL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 646 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 647 ISRAEL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 648 ISRAEL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 649 ISRAEL CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)

TABLE 650 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 651 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 652 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 653 REST OF MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)